November 2024 US Exchange Standouts: Promising Penny Stocks

As the U.S. stock market navigates a "sometimes-bumpy path" toward its inflation target, as noted by Fed Chair Jerome Powell, investors are closely watching for opportunities amidst fluctuating indices. Penny stocks, though an older term, remain relevant by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with strong financials and clear growth potential, investors may find promising opportunities within this often-overlooked segment of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8155	$5.95M	★★★★★★
RLX Technology (NYSE:RLX)	$1.63	$2.05B	★★★★★★
Flexible Solutions International (NYSEAM:FSI)	$3.72	$52.54M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$155.89M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
So-Young International (NasdaqGM:SY)	$1.25	$81.58M	★★★★☆☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.24	$8.98M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.70	$127.43M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.94	$83.45M	★★★★★☆

Click here to see the full list of 748 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Cocrystal Pharma (NasdaqCM:COCP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cocrystal Pharma, Inc. is a biotechnology company dedicated to discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases, with a market cap of $18.01 million.

Operations: Cocrystal Pharma, Inc. does not report any specific revenue segments.

Market Cap: $18.01M

Cocrystal Pharma, Inc., with a market cap of US$18.01 million, is a pre-revenue biotechnology company focused on antiviral treatments. Despite being debt-free and having short-term assets of US$19.7 million that cover both its short- and long-term liabilities, the company remains unprofitable with a negative return on equity of -103.09%. Recent earnings reports indicate increasing losses, with a net loss of US$4.94 million for Q3 2024 compared to US$4.17 million in the previous year. The management team is experienced but faces challenges as earnings are forecasted to decline over the next three years without expected profitability improvements.

• Click here and access our complete financial health analysis report to understand the dynamics of Cocrystal Pharma.
• Assess Cocrystal Pharma's future earnings estimates with our detailed growth reports.

PHX Minerals (NYSE:PHX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: PHX Minerals Inc. is a natural gas and oil mineral company operating in the United States with a market capitalization of $127.43 million.

Operations: The company generates revenue of $31.94 million from exploring, developing, producing, and selling oil, NGL, and natural gas.

Market Cap: $127.43M

PHX Minerals, with a market cap of US$127.43 million, has shown stable operations despite recent challenges. The company reported Q3 2024 revenue of US$9.14 million, slightly down from last year, and net income of US$1.1 million compared to US$1.9 million previously. While earnings growth has been negative recently, PHX maintains satisfactory debt levels with well-covered interest payments and operating cash flow covering its debt efficiently. However, profit margins have decreased from 34.1% to 14.8%. Investor activism by Edenbrook Capital may influence future strategic decisions regarding management and capital structure adjustments at PHX Minerals Inc.

• Click to explore a detailed breakdown of our findings in PHX Minerals' financial health report.
• Gain insights into PHX Minerals' outlook and expected performance with our report on the company's earnings estimates.

Zepp Health (NYSE:ZEPP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Zepp Health Corporation operates as a smart wearable and health technology company globally, with a market cap of $46.63 million.

Operations: The company's revenue from the People's Republic of China amounts to $237.24 million.

Market Cap: $46.63M

Zepp Health, with a market cap of US$46.63 million, remains unprofitable as losses have grown annually by 64.4% over five years. Despite this, the company has regained NYSE compliance after a stock split and continues to cover debt with cash flow effectively. Revenue from China stands at US$237.24 million, though recent sales have declined significantly year-over-year. Strategic partnerships like the one with HYROX aim to leverage Zepp's Amazfit brand in smart wearables, potentially enhancing its market position despite ongoing volatility and management changes that could impact future performance stability.

• Take a closer look at Zepp Health's potential here in our financial health report.
• Explore Zepp Health's analyst forecasts in our growth report.

Turning Ideas Into Actions

• Gain an insight into the universe of 748 US Penny Stocks by clicking here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com